Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “IPSS Risk Category Intermediate-2”

32 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 32 results

Testing effectiveness (Phase 2)UnknownNCT00885508
What this trial is testing

The Efficacy and Safety of Lenalidomide Combined to Escalating Doses of Chemotherapy in Intermediate-2-or High Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) With Del 5q

Who this might be right for
Myelodysplastic SyndromeChronic Myelomonocytic LeukemiaAcute Myeloid Leukemia
Groupe Francophone des Myelodysplasies 85
Testing effectiveness (Phase 2)WithdrawnNCT00867061
What this trial is testing

Efficacy and Safety of 5-day Dosing of ON 01910.Na in Intermediate-1,-2, or High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT02706899
What this trial is testing

Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS

Who this might be right for
Myelodysplastic Syndrome
Seagen Inc. 19
Testing effectiveness (Phase 2)Study completedNCT00531232
What this trial is testing

A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)

Who this might be right for
Myelodysplastic SyndromesSecondary Acute Myeloid Leukemia (AML)
Genzyme, a Sanofi Company 38
Large-scale testing (Phase 3)Active Not RecruitingNCT05883956
What this trial is testing

A Study Comparing Treatment Preference Between Oral Decitabine/Cedazuridine and Azacitidine in Myelodysplastic Syndrome, Low-Blast Acute Myeloid Leukemia, or Chronic Myelomonocytic Leukemia

Who this might be right for
Myelodysplastic SyndromesLeukemia, Myeloid, AcuteLeukemia, Myelomonocytic, Chronic+1 more
Otsuka Australia Pharmaceutical Pty Ltd 13
Early research (Phase 1)WithdrawnNCT02075034
What this trial is testing

Three Dosing Schedules of Oral Rigosertib in MDS Patients

Who this might be right for
Myelodysplastic Syndrome
Traws Pharma, Inc.
Testing effectiveness (Phase 2)UnknownNCT00022321
What this trial is testing

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Who this might be right for
Myelodysplastic Syndromes
Jonsson Comprehensive Cancer Center
Large-scale testing (Phase 3)Ended earlyNCT02158936
What this trial is testing

Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

Who this might be right for
Thrombocytopaenia
Novartis Pharmaceuticals 356
Testing effectiveness (Phase 2)Study completedNCT02426086
What this trial is testing

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Who this might be right for
Myelofibrosis
Geron Corporation 107
Testing effectiveness (Phase 2)Study completedNCT01420770
What this trial is testing

Phase 2 Study of SAR302503 in Patients With Myelofibrosis

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 30
Testing effectiveness (Phase 2)Study completedNCT02281084
What this trial is testing

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Who this might be right for
Myelodysplastic Syndromes
Celgene 65
Testing effectiveness (Phase 2)Study completedNCT01305460
What this trial is testing

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Who this might be right for
Myelodysplastic Syndrome
Groupe Francophone des Myelodysplasies 27
Testing effectiveness (Phase 2)Study completedNCT01692366
What this trial is testing

Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly

Who this might be right for
Myelofibrosis
Bristol-Myers Squibb 8
Testing effectiveness (Phase 2)Ended earlyNCT02010645
What this trial is testing

Eltrombopag With Decitabine in Advanced Myelodysplastic Syndrome (MDS)

Who this might be right for
Leukemia
M.D. Anderson Cancer Center 6
Large-scale testing (Phase 3)Study completedNCT01437787
What this trial is testing

Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis

Who this might be right for
Hematopoietic Neoplasm
Bristol-Myers Squibb 289
Early research (Phase 1)Looking for participantsNCT07469891
What this trial is testing

PRT12396 in Participants With Select Myeloproliferative Neoplasms

Who this might be right for
Polycythemia Vera (PV)Myelofibrosis (MF)Myeloproliferative Neoplasms (MPNs)+3 more
Prelude Therapeutics 100
Testing effectiveness (Phase 2)Study completedNCT00776503
What this trial is testing

Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 52
Testing effectiveness (Phase 2)Study completedNCT01088373
What this trial is testing

Lenalidomide Combined to Azacitidine in Intermediate-2 or High Risk MDS With Del 5q

Who this might be right for
Myelodysplastic Syndromes
Groupe Francophone des Myelodysplasies 50
Testing effectiveness (Phase 2)Ended earlyNCT02152956
What this trial is testing

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Who this might be right for
AML
MacroGenics 244
Testing effectiveness (Phase 2)Not Yet RecruitingNCT02944955
What this trial is testing

BLEX 404 Oral Liquid in Patients With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-Risk Myelodysplastic Syndrome (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Who this might be right for
Myelodysplastic Syndrome (MDS)
BioLite, Inc. 52
Load More Results